Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Files An 8-K Other Events
Item 8.01.
| Other Events. |
In connection with the previously announced public offering (the
Offering) by Accelerate Diagnostics, Inc. (the Company) of
2,750,000 shares of its common stock, par value $0.001 per share,
that closed May 15, 2017, the underwriters have partially
exercised their option to purchase an additional 335,484 shares
of common stock (the Option Shares) from the Company at the
public offering price of $28.85 per share, less the underwriting
discounts and commissions. The exercise of the option to purchase
additional shares brings the total number of shares of common
stock sold in the Offering to 3,085,484, resulting in total net
proceeds of approximately $82.9 million. The sale of the Option
Shares closed on June 14, 2017.
A copy of the opinion of Snell Wilmer L.L.P. relating to the
legality of the issuance and sale of the Option Shares is
attached hereto as Exhibit 5.1.
| Item 9.01. | Financial Statements and Exhibits. |
(d)Exhibits.The following material is filed as an exhibit to this
Current Report on Form 8-K:
| Exhibit | |||
| Number | Description | ||
| 5.1 |
Opinion of Snell Wilmer L.L.P. |
||
| 23.1 |
Consent of Snell Wilmer L.L.P. (included in Exhibit 5.1) |
||
About Accelerate Diagnostics, Inc. (NASDAQ:AXDX)
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types. The Company is focused on the development of a rapid diagnostic platform, the Accelerate ID/AST System (ID/AST System or Accelerate ID/AST System), intended for the diagnosis of infectious pathogens. The ID/AST System utilizes genotypic technology to identify (ID) infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. The ID/AST System features walk-away automation and consists of a fixed instrument and single-use test kit.
